Determining the value of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain by multi-criteria decision analysis (MCDA)

Category Systematic review
JournalValue in Health
Year 2017
This article has no abstract
Epistemonikos ID: 02c0d15b6288ff66b573f266eca8638a0392b271
First added on: Feb 08, 2025